Funding for this research was provided by:
National Institutes of Health (UG3 OD-023253, R01 AI-114552, U01 AI-087881, R01 AI-108588)
Received: 27 December 2016
Accepted: 14 December 2017
First Online: 3 January 2018
Ethics approval and consent to participate
: Written informed consent was obtained from the parent or guardian of all participating infants. The institutional review board at each of the participating hospitals approved the study.
: Not applicable.
: JMM has provided bronchiolitis-related consultation for Regeneron. NJA and JFP own shares at Diversigen Inc., a microbiome research company. PAP provided bronchiolitis-related consultation for Gilead, Novavax, Ablynx, and Regeneron. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.